Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España

Actualizado agosto 2023

Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

Para iniciar la búsqueda, teclee el texto en la barra a continuación.

EudraCT-NumberNCTCÓDIGO-ESTUDIOTÍTULO ESTUDIO FASEINDICACIÓNESTADOMEDICACIÓNCENTROPROMOTOR
2018-004334-15
4234113SC103A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid TumorsPhase IThyroid & HNSCC, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selectedadvanced/metastatic solid tumorsRECLUTANDOSO-C101 PembrolizumabH.U. Vall d´Hebron(BCN)
H. Sanchinarro (Madrid)
SOTIO
UNK4985604DAY101-102A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway AberrationsPhase I/IIThis is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.RECLUTANDOTovorafenib
Pimasertib
H. Clinic Barcelona
H. U. Vall d'Hebron
H. U. Ramón y Cajal
Day One Biopharmaceuticals, Inc.
UNK4731467FW-2020-1A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid TumorPhase I/IICohort: Papillary Thyroid CancerRECLUTANDOCM-24
Nivolumab,
Nab paclitaxel Gemcitabine
H. Vall d' Hebron
H. 12 Octubre
H. Quiron Salud Valencia
Start_Sanchinarro(Madrid)
Famewave Ltd
Bristol-Myers Squibb
2018-001066-42
3753919GETNE-T1812A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY TrialPhase IIThis is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.
Cohort 1: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle. Cell and poorly-differentiated thyroid carcinoma (DTC).
Cohort 2: Advanced medullary thyroid carcinoma (MTC).
Cohort 3: Advanced anaplastic thyroid cancer (ATC)
RECLUTANDODurvalumab
Tremelimumab
C.U.N.
H.U. Vall d´Hebron (Barcelona)
ICO Hospitalet
H.U. Morales Meseguer (Murcia)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
H.U. La Paz (Madrid)
H.U. Virgen de la Victoria (Málaga)
H.U. Clínic (Barcelona)
M.D. Anderson (Madrid)
H.U. Sanchinarro (Madrid)
H.U. Clínico San Carlos (Madrid)
C.H. Castellón
IVO Valencia
H.U. Alvaro Cunqueiro (Vigo)
Spanish Group of Neuroendocrine Tumors (GETNE)
2016-003616-133093116TPX-0005-01A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Phase II (in Spain)Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts.
RECLUTANDORepotrectinib (TPX-0005)C.U.N.
H.U. Dexeus (Barcelona)
H.U. Vall d´Hebron (Barcelona)
M.D. Anderson (Madrid)
Start_F.J.Díaz (Madrid)
Start_Sanchinarro (Madrid)
H.U. 12 de Octubre (Madrid)
IVO Valencia
Turning Point Therapeutics, Inc.
2015-002067-41
CTIS: 2022-500397-34-00
26280673475-158A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)Phase IIThyroid Carcinoma
Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)
RECLUTANDOPembrolizumabH.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
Merck Sharp & Dohme Corp
2020-001847-164589845BO41932Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialPhase IITreatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.RECLUTANDOPralsetinib
Entrectinib
Belvarafenib
H.U. Vall d´Hebron (Barcelona)
C.U.N.
H.U. 12 de Octubre (Madrid)
H.U. La Paz (Madrid)
H.U. La Fe (Valencia)
Hoffmann-La Roche
UNK5660954GETNE-T2216Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.Phase IICABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine refractoryRECLUTANDOCabozantinibH. U. Central de Asturias
H. U. Rey Juan Carlos
C. H. U. A Coruña
H. U. Vall d'Hebron
H. Clínic de Barcelona
H. U. Ramón y Cajal
H. Clínico San Carlos
H. U. 12 de Octubre
H. Morales Meseguer (Murcia)
C. A. U. de Salamanca
Grupo Espanol de Tumores Neuroendocrinos
2019-001978-284211337J2G-MC-JZJBA Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)Phase IIIMale or female patients with progressive, advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid CancerRECLUTANDOSelpercatinib
Cabozantinib
Vandetanib
H.U. Virgen de la Victoria (Málaga)
H.U. Clínico San Carlos (Madrid)
H.U. 12 de Octubre (Madrid)
H.U. La Paz (Madrid)
H.U. Ramón y Cajal (Madrid)
H.U. Gregorio Marañón (Madrid)
ICO Girona
ICO Hospitalet
H.U. Vall d´Hebron (Barcelona)
C.U.N.
H.U. Miguel Servet (Zaragoza)
Loxo Oncology, Inc
2020-005269-154760288CO42865A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)Phase IIIRET-Mutated Medullary Thyroid Cancer (MTC) is a form of thyroid carcinoma which originates from parafollicular cells and which produce the hormone calcitonin.RECLUTANDOPralsetinib
Cabozantinib
Vandetanib
H. Clínico de Santiago de Compostela
C.U.N.
H.U. Vall d´Hebron (Barcelona)
H. Clínic (Barcelona)
H.U. Ramón y Cajal (Madrid)
H. Sanchinarro (Madrid)
H.U. Virgen del Rocío (Sevilla)
H. Regional de Málaga
MD Anderson (Madrid)
H.U. Reina Sofía (Córdoba)
Hoffmann-La Roche
UNK3906331J2G-OX-Y001Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationExpanded AccessMedullary Thyroid Cancer
Papillary Thyroid Cancer
Other Solid Tumors With Evidence of Activating RET Alteration
DISPONIBLESelpercatinibH.U. Vall d´Hebron (Barcelona)
Start_Sanchinarro (Madrid)
Loxo Oncology, Inc.
N.A3765333REGETNE-TiroidesDescriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and AnaplasticDescriptive ObservationalNARECLUTANDONAH.U. Vall d´Hebron (Barcelona)Grupo Espanol de Tumores Neuroendocrinos

Puede seleccionar el número de filas a representar entre: 4, 8 o 10